Mercury Pharmaceuticals UK

Oct 2026

Improving healthcare sustainability through carbon data

Healthcare sustainability data can identify emissions hotspots and improve operational decision-making across healthcare and life sciences.

Oct 2026

Bonn researchers successfully rejuvenate human cells in a test tube

Researchers from the University Hospital of Bonn and the University of Bonn have succeeded in dramatically rejuvenating human cells in a test tube.

Oct 2026

Study explains why cancer immunity declines faster in males

Lutz Menzel, PhD, formerly of the Department of Radiation Oncology within the Mass General Brigham Cancer Institute, and Tim Padera, PhD, currently of the Mass General Brigham Cancer Institute, are the lead and senior authors of a paper published in Nature Aging, "Lymph node contraction links sex-biased naive CD8 T cell decline to compromised antigen recognition during middle age."

Oct 2026

Study explains why cancer immunity declines faster in males

Oct 2026

Early-onset Alzheimer's patients accumulate symptoms years before diagnosis

People who develop Alzheimer's disease before the age of 65 experience a growing range of health problems and increasing use of healthcare services years before diagnosis.

Oct 2026

Lynch syndrome patients rarely use aspirin for cancer prevention

According to international studies, taking Acetylsalicylic acid daily can protect people with Lynch syndrome from developing colorectal cancer - even at low doses. Researchers from the University Hospital Bonn (UKB), the University of Bonn, and the Center for Integrated Oncology (CIO) Bonn, in collaboration with the self-help organization SemiColon, have now found that these scientific findings have so far been insufficiently incorporated into clinical practice.

Oct 2026

Brain injuries change how the hypothalamus responds to stress

Researchers from the Department of Cell Biology, Genetics and Physiology at the University of Malaga have led an international scientific team that has studied how a traumatic brain injury caused by a severe blow to the head conditions the brain's long-term response to subsequent stress situations.

Oct 2026

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.